Pfizer, along with BioNTech, used breakthrough mRNA technology to create its COVID-19 vaccine. The potential of this new tech could transform science, leaders at the company said.

Annaliesa Anderson, a leader in vaccine research, shared how the pandemic changed Pfizer.
Anderson said employees embraced a “light-speed mentality” of doing things faster and simpler.
The company will apply mRNA tech to other areas and use new ways of thinking to solve problems.
This article is part of a series called “Culture of Innovation” exploring how companies are setting the stage for innovation, transformation, and growth.

The world isn’t the same place it was three years ago, and neither is Pfizer. 

The biopharmaceutical giant, along with its partner BioNTech, was one of the first to develop a marketable vaccine for COVID-19 using nascent mRNA technology. It was one of the fastest developments of a vaccine for modern medicine, forcing execs to ask what’s next for a company that had shown it could compress the drug-creation process. 

Pfizer, which has said it expects to pull in $32 billion in sales from its COVID vaccine this year, knows that it’s set a high standard for innovation, collaboration, and R&D. COVID-19 forced a “paradigm shift” within the company, where execs and employees alike had to think and act differently, according to Pfizer’s Uwe Schoenbeck, chief scientific officer of external research, development, and innovation. 

“Pfizer’s pandemic response focused on external partnership, reduction of bureaucracy, and a purpose-driven culture,” Schoenbeck told Insider. “It taught us that what seems impossible at one point in time can be achieved, but also that it requires us to do things differently.”

For Pfizer, priorities for the future include using mRNA technology to develop vaccines for other diseases like respiratory syncytial virus, known as RSV, the flu, as …read more

Source:: Business Insider


(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *